Literature DB >> 19089489

The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis.

Ingo H Tarner1, Ulf Müller-Ladner, Christine Uhlemann, Uwe Lange.   

Abstract

Serial mild whole-body hyperthermia is a widely used balneotherapy modality for clinically inactive ankylosing spondylitis (AS) in rehabilitative medicine. Thus far, the mechanisms of its favorable influence on the symptoms of AS are not completely understood. We therefore analyzed the effect of mild whole-body hyperthermia on the systemic levels of pivotal proinflammatory cytokines. Twelve male subjects with AS and 12 healthy control subjects received nine cycles of whole-body hyperthermia (target body core temperature, 38.5 degrees C; duration, 50 min). Serum samples were taken at the beginning of the last cycle and at 1, 6, and 24 h for measurement of tumor necrosis factor alpha, interleukin 1beta and interleukin 6. Significant differences of cytokine levels were found between both groups. In AS patients, hyperthermia caused a significant reduction of all cytokines by 40-50%. Thus, serial mild whole-body hyperthermia in AS results in heat-induced changes of the proinflammatory cytokine network.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19089489     DOI: 10.1007/s10067-008-1059-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  Sustained response to anakinra in ankylosing spondylitis.

Authors:  A N Bennett; A L Tan; L C Coates; P Emery; H Marzo-Ortega; D McGonagle
Journal:  Rheumatology (Oxford)       Date:  2007-12-11       Impact factor: 7.580

3.  Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis.

Authors:  Z N Tutuncu; A Bilgie; L G Kennedy; A Calin
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

4.  Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis.

Authors:  Monica Vazquez-Del Mercado; Araceli Garcia-Gonzalez; José Francisco Muñoz-Valle; Trinidad Garcia-Iglesias; Gloria Martinez-Bonilla; Guislaine Bernard-Medina; Adriana Sanchez-Ortiz; José M Ornelas-Aguirre; Mario Salazar-Paramo; Jorge I Gamez-Nava; Laura Gonzalez-Lopez
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

5.  Suppression of contact sensitivity by local hyperthermia treatment due to reduced Langerhans cell population in mice.

Authors:  A Yoshioka; Y Miyachi; S Imamura; M Hiraoka; S Jo; M Abe
Journal:  Br J Dermatol       Date:  1989-04       Impact factor: 9.302

6.  [Quantitative changes in peripheral T-lymphocytes during hyperthermia (author's transl)].

Authors:  M Bühring; L Bork-Wölwer; H Krippner; K Pirlet
Journal:  MMW Munch Med Wochenschr       Date:  1977-12-09

7.  [Hyperthermia treatment of ankylosing spondylitis].

Authors:  H D Hentschel; F Nold; I Regehr
Journal:  Verh Dtsch Ges Rheumatol       Date:  1969

8.  Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis.

Authors:  U Lange; J Teichmann; H Stracke
Journal:  Eur J Med Res       Date:  2000-12-29       Impact factor: 2.175

9.  Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism.

Authors:  M Rudwaleit; S Siegert; Z Yin; J Eick; A Thiel; A Radbruch; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

10.  Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.

Authors:  E Toussirot; P Lafforgue; J Boucraut; P Despieds; A Schiano; D Bernard; P C Acquaviva
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

View more
  18 in total

1.  [Molecular physical medicine].

Authors:  U Lange
Journal:  Z Rheumatol       Date:  2012-07       Impact factor: 1.372

2.  The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis.

Authors:  Uwe Lange; Gabriel Dischereit; Ingo Tarner; Klaus Frommer; Elena Neumann; Ulf Müller-Ladner; Bernhard Kürten
Journal:  Clin Rheumatol       Date:  2016-04-06       Impact factor: 2.980

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.3 Nonpharmaceutical therapeutic measures].

Authors:  U Kiltz; W Mau; U Smolenski; U Repschläger; E Böhle; M Stemmer; U Oberschelp; E Schneider; B Swoboda; H Böhm; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 4.  [Molecular physical medicine in rheumatic disease patterns].

Authors:  U Lange
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

5.  Effect of spa therapy with saline balneotherapy on oxidant/antioxidant status in patients with rheumatoid arthritis: a single-blind randomized controlled trial.

Authors:  Mine Karagülle; Sinan Kardeş; Oğuz Karagülle; Rian Dişçi; Aslıhan Avcı; İlker Durak; Müfit Zeki Karagülle
Journal:  Int J Biometeorol       Date:  2016-06-21       Impact factor: 3.787

Review 6.  Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?

Authors:  Antonella Fioravanti; Luca Cantarini; Giacomo Maria Guidelli; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

7.  Evaluation of a special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis.

Authors:  Philipp Klemm; Ole Hudowenz; Thomas Asendorf; Gabriel Dischereit; Ulf Müller-Ladner; Uwe Lange; Ingo H Tarner
Journal:  Clin Rheumatol       Date:  2020-01-08       Impact factor: 2.980

8.  Circulating white blood cell count and measures of adipose tissue inflammation predict higher 24-h energy expenditure.

Authors:  Jianying He; Duc Son Le; Xiaoyuan Xu; Michael Scalise; Anthony W Ferrante; Jonathan Krakoff
Journal:  Eur J Endocrinol       Date:  2009-11-24       Impact factor: 6.664

9.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

10.  Higher percentage of CD3⁺CD154⁺ T lymphocytes predicts efficacy of TNF-α inhibitors in active axial SpA patients.

Authors:  Zhiming Lin; Qu Lin; Zetao Liao; Qiuxia Li; Fucheng Zhang; Qiujing Wei; Shuangyan Cao; Jieruo Gu
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.